Sign in Create account
Sign in and upgrade to a paid plan to export bulk/block deals as CSV.

IOL Chemicals and Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: IOLCP BSE: 524164
₹205.71
▼ -3.68 (-1.76%)
Oct. 5, 2026 · NSE · nse_bhavcopy
Quality
71/100
Strong
Valuation
26/100
Expensive
Momentum
52/100
Neutral

QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹6,038 Cr
PE (TTM)
35.9
Industry median 35.6 (152 companies)
Price to Book
3.4
PEG (TTM)
-1.0
Institutions holding %
5.30%
FII + DII, latest filed period
Piotroski Score
7
Relative return vs Nifty50, qtr %
66.5
Relative return vs Sector, qtr %
44.2
Free Cash Flow
₹41 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
89.66%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
59.80%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
18.56%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
89.87%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
37.08%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.78
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.07
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
17.17
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
8.53%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
11.95%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
9.50%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
5.32%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
10.49%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
7.65%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

6 of 8 met
  • Yes Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • Yes Piotroski F-score is 7 or more (score 7)
  • Yes Debt to equity is below 0.5 (0.07)
  • No Return on equity is 15% or more (7.7%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

4 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.8%
Low 204.3500 · High 214.4000
1W return
4.8%
Low 196.2400 · High 214.4000
1M return
2.9%
Low 173.5500 · High 219.0400
52W return
98.0%
Low 67.1900 · High 219.0400
Lifetime High ₹878.6500 (Aug. 25, 2020)
Lifetime Low ₹15.6500 (Feb. 7, 2014)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
205.3
10D
203.6
20D
199.6
50D
184.1
100D
161.6
200D
119.4

Delivery and volume

Day avg. delivery
33.8%
Week avg. delivery
33.6%
Month avg. delivery
30.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

208.15
Pivot
First resistance211.96
Second resistance218.20
Third resistance222.01
First support201.91
Second support198.10
Third support191.86
Day RSI57.4
Day MFI63.4
Day MACD6.41
Day MACD signal7.21

Beta

1M2.85
3M0.70
1Y1.13
3Y1.21

Price change analysis

↑ 2.9%
Over 1 Month
LowHigh
173.55219.04
↑ 42.4%
Over 3 Months
LowHigh
143.55219.04
↑ 159.0%
Over 6 Months
LowHigh
77.70219.04
↑ 98.0%
Over 1 Year
LowHigh
67.19219.04
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 35.9 (own history: 4.7–27.8)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹756 Cr
Net profit (June 30, 2026)
₹64 Cr
Basic EPS (June 30, 2026)
₹2.2000

Ranks #57 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter62.28%
  • Mutual funds0.02%
  • FII/FPI4.87%
  • Other DII0.41%
  • Public32.42%

Largest holders

NameCategoryShares %Shares
NM MERCHANTILES LIMITEDPromoter21.8800%64214845
MAYA DEVI POLYCOT LIMITEDPromoter21.7900%63945330
NCVI ENTERPRISES LIMITEDPromoter16.5800%48655000
VARENDER GUPTAPromoter2.0400%5979325

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings increased from 57.48% to 62.28% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 1.72% to 4.87% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.02% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 15 insider trades, 25 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
20 Mar 2026 NCVI Enterprises Limited Promoter group Buy 0 ₹0
19 Mar 2026 Mayadevi Polycot Limited Promoter group Buy 0 ₹0
19 Mar 2026 NCVI Enterprises Limited Promoter group Buy 0 ₹0
18 Mar 2026 NCVI ENTERPRISES LIMITED Promoter group Buy 0 ₹0
18 Mar 2026 Mayadevi Polycot Limited Promoter group Buy 0 ₹0
24 Aug 2021 Damandeep Singh Other Sell 0 ₹0
24 Aug 2021 Damandeep Singh Other Sell 0 ₹0
7 Apr 2021 Damandeep Singh Employee / designated person Sell 0 ₹0
17 Mar 2021 Damandeep Singh Employee / designated person Sell 0 ₹0
26 Jun 2020 NCVI ENTERPRISES LIMITED Promoter group Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 195 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
8 Jul 2026 QE SECURITIES LLP Bulk Buy 1,549,954 168.7700 NSE
8 Jul 2026 QE SECURITIES LLP Bulk Sell 1,515,110 170.4900 NSE
8 Jul 2026 MICROCURVES TRADING PRIVATE LIMITED Bulk Buy 1,574,122 170.9700 NSE
8 Jul 2026 MICROCURVES TRADING PRIVATE LIMITED Bulk Sell 1,574,122 171.0400 NSE
8 Jul 2026 HRTI PRIVATE LIMITED Bulk Sell 2,161,991 169.6100 NSE
8 Jul 2026 HRTI PRIVATE LIMITED Bulk Buy 1,147,860 168.7200 NSE
7 Jul 2026 POLUNIN EMERGING MARKETS SMALL CAP FUND LLC Bulk Buy 4,419,222 166.6500 NSE
9 Sep 2025 QE SECURITIES LLP Bulk Sell 2,073,742 117.4700 NSE
9 Sep 2025 QE SECURITIES LLP Bulk Buy 1,981,022 117.5200 NSE
9 Sep 2025 MUSIGMA SECURITIES Bulk Buy 1,921,093 117.8200 NSE

All bulk and block deals →

Corporate Actions

Full history (2 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Industrial Organics Limited to IOL Chemicals & Pharmaceuticals Limited
—NAME_CHANGEName changed from Trident Alco-Chem Ltd to IOL Chemicals & Pharmaceuticals Limited

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
10 Aug 2026 Financial Results Yes
20 May 2026 Financial Results Yes
11 Feb 2026 Financial Results/Dividend Yes
11 Nov 2025 Financial Results Yes
7 Aug 2025 Financial Results Yes

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Insider Trading / SAST IOL Chemicals & Pharmaceuticals Ltd - 524164 - Closure of Trading Window
25 Sep 2026 Company Update IOL Chemicals & Pharmaceuticals Ltd - 524164 - Grant Of Certificate Of Suitability (CEP) For Fenofibrate - Process II
21 Sep 2026 Company Update IOL Chemicals & Pharmaceuticals Ltd - 524164 - Dispatch Of Reminder Letter To Shareholders To Update KYC
11 Sep 2026 Company Update IOL Chemicals & Pharmaceuticals Ltd - 524164 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
10 Sep 2026 Company Update IOL Chemicals & Pharmaceuticals Ltd - 524164 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
9 Sep 2026 Company Update IOL Chemicals & Pharmaceuticals Ltd - 524164 - Expansion Of Ibuprofen Capacity, New CDMO Business For Pharmaceutical Formulations And Dedicated Specialty Chemicals Manufacturing Facility

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.07)
  • Comfortable interest coverage (17.2x)
  • Healthy liquidity (Current Ratio 1.78)
  • Strong revenue growth YoY (37.1%)

Weaknesses

  • Low Return on Equity (7.7%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (35.9) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about IOL Chemicals and Pharmaceuticals Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.